Echinocandin resistance among Candida isolates at an academic medical centre 2005-15: analysis of trends and outcomes. [PDF]
J Antimicrob Chemother, 2018 McCarty TP +6 more
europepmc +1 more source
Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy. [PDF]
Antimicrob Agents Chemother, 2018 Khan Z +6 more
europepmc +1 more source
Rapid Detection of FKS-Associated Echinocandin Resistance in Candida glabrata. [PDF]
Antimicrob Agents Chemother, 2016 Zhao Y +7 more
europepmc +1 more source
Global surveillance of <i>Candida albicans</i>: MIC distributions, resistance patterns, and temporal trends from the Antimicrobial Testing Leadership and Surveillance program (2015-2024). [PDF]
Antimicrob Agents ChemotherCai G, Zhang Z.
europepmc +1 more source
Echinocandins have an alternative mode of action on biomimetic membranes that is not directly related to the functioning of (1,3) beta-glucan synthase. [PDF]
Cell Death DiscovMalykhina AI +5 more
europepmc +1 more source
Resistance to echinocandin-class antifungal drugs [PDF]
Drug Resistance Updates, 2007 Invasive fungal infections cause morbidity and mortality in severely ill patients, and limited drug classes restrict treatment choices. The echinocandin drugs are the first new class of antifungal compounds that target the fungal cell wall by blocking beta-1,3-d-glucan synthase.
David Perlin
exaly +3 more sources
Related searches:
Candidemia surveillance in Iowa: emergence of echinocandin resistance
Diagnostic Microbiology and Infectious Disease, 2014We performed prospective surveillance for candidemia at 14 Iowa hospitals in 2011-2012. A total of 163 episodes were analyzed. Candida albicans (n = 69 [42%]) and Candida glabrata (n = 58 [36%]) were the most common species. Antifungal resistance was uncommon; 9% of C.
Eiyu Matsumoto +2 more
exaly +3 more sources